Moreover, previous studies demonstrated that in bladder cancer, HER2 overexpression strongly correlated with tumour progression and poor prognosis and, unlike BC, HER2 genomic amplification is not a common mechanism [80, 81]. This evidence concerns the gene ERBB2 and urinary bladder cancer.